Skip to content

D&A at other companies

Incyte logo
IncyteINCY
$23.8M+6.4%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$16.41M-25.6%
UroGen Pharma logo
UroGen PharmaURGN
$75K+4.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.19M-7.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$559K+26.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$121K+3.4%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s D&A?
Tyra Biosciences, Inc. (TYRA) reported D&A of $138K in Q1 2026.
How has Tyra Biosciences, Inc.'s D&A changed year-over-year?
Tyra Biosciences, Inc.'s D&A decreased by 3.5% year-over-year, from $143K to $138K.
What is the long-term trend for Tyra Biosciences, Inc.'s D&A?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s D&A has grown at a 40.5% compound annual growth rate (CAGR), from $140K to $546K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.